Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘durvalumab’

Kicking KRAS to the kerb

Singapore – host for WCLC23

In our second post from the World Congress on Lung Cancer (WCLC) being held in Asia this year, we review over half a dozen datasets on KRAS developments.

Here we cover preclinical and clinical updates, monotherapy and combinations, as well as some likely future directions based on emerging data…

For the record there were also a couple of controversial surprises in store this year…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

WCLC23 – SCLC highlights and lowlights

Can we see the wood from the trees in ES-SCLC?

Much of the noise and attention in lung cancer is usually focused on non-small cell lung cancer (NSCLC) at cancer conferences.

While it has a greater prevalence than its more difficult to treat cousin, small-cell lung cancer (SCLC), the good news is there are now quite a few emerging novel agents and targets being evaluated in this disease.

Here we highlight and discuss some of the progress being made (or not) in the context of the broader landscape…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

What’s hot in lung cancer?

Gardens by the Bay in Singapore

With the abstract titles now available for the World Congress in Lung Cancer (WCLC), it’s time to take a look at what we can expect for the meeting coming up in early September.

In our latest conference Preview, we have highlighted several education sessions to look at, as well as ten key oral presentations to watch out for…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Divvying it up at ASCO23

There’s more than one way to look at data despite the same top line results

Beyond the obvious, what else was coming out at ASCO this year?

It’s time to divvy up the spoils and explore some intriguing trial results not in the mainstream consciousness.

Well there is one major trial we critique in this latest review, although perhaps with a rather different take on the data as it could be considered in a more controversial light when you look at the details.

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

New controversies in GI malignancies

Gastronomic delicacies in Paris

In our second ESMO 2022 Preview we take a look at some of the key trials being presented in gastrointestinal cancers and highlight what to watch out for on this front.

While a few readers will no doubt be keen to skip to the KRAS section to learn more about sotorasib and adagrasib in colorectal cancer, make no mistake there’s plenty going on in new product development in several other GI cancers too, both with targeted therapies as well as immunotherapies.

Curious to learn more?

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

New directions in small cell lung cancer

Linie 30 Florisdorf, Vienna

With all the frequent attention on lung cancer of late – mostly on the most common form, non-small cell lung cancer – it’s easy to forget small cell lung cancer (SCLC) in the rush to highlight new developments.

It’s time to talk turkey about old and new agents in the quest to improve outcomes for people with this dismal disease.

The good news is there are also a raft of scientific developments emerging, which may potentially help us better identify discrete subsets and enable the matching of appropriate regimens to the underlying biology.

At the World Conference in Lung Cancer this week in Vienna we’ve been following the numerous trials (and tribulations!) of progress in this niche, with a look at several key readouts through the lens of a thoracic lung cancer specialist.

What does he have to say and where are things heading next for the field?

To find out more, check out the interview below…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

ASCO22 Highlights from Day 1

Graffiti in Adams Morgan, Chicago

After weeks of waiting ASCO has finally arrived!

There are a surprising number of intriguing presentations at this meeting for those prepared to hunt off the radar, with some interesting implications to be considered in a broader context.

There were several to be found even on the very first day of action – they don’t all have to be massive phase 3 studies to make an impact.

Here we look at some of the highlights we heard about in between doing expert interviews for colour commentary and context.  One such example is included here where it turned out there were some strategic commercial considerations involved as well…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Important changes to watch out for in the GI cancer landscape

It’s that time of year when the ASCO GI and GU Symposiums come around, with GI up on deck first.

End of a rocky road for some GI cancers

Finally, after what seems like positive trials being few and far between we have a veritable raft of them to highlight, mostly for good reasons instead of bemoaning yet another negative phase 3 study – exciting times!

There’s also some up and coming agents in earlier development to watch out for, as well as the potential for additional indications for established drugs already approved by Health Authorities – what’s not to like?

In our latest conference Preview, we highlight some important trials and discuss them in the context of what’s gone before them to evaluate whether they will make an impact – or not…

BSB subscribers can read up on our ongoing commentary and analysis from the ASCO GI symposium – you can either log-in or click to access the back story behind the latest innovations.

This content is restricted to subscribers

What can we learn from early stage IO trials?

The search continues to find novel IO approaches to be used either with or instead of checkpoint blockade in a number of advanced solid tumours.

Plain sailing or a rocky road ahead?

In the recent past, much of the combination strategies tended to focus almost exclusively on the adaptive immune system with limited results given the majority of people still do not respond to these therapies.

What if we could utilise the innate immune system in a complementary fashion much more effectively than we have previously?

In order to achieve this nirvana, we need to develop either new technologies to facilitate jumpstarting the stalled immune system or think creatively about doublet and triplet regimens which make sense in tackling the different immune defects present.

Here’s a look at two such early approaches where we explore the latest data and put it context of both what’s known, and also where we’re likely headed…

BSB subscribers can read up on our ongoing commentary and analysis from the cancer conference season – you can either log-in or click to access our latest analysis.

This content is restricted to subscribers

COAST to coast – contemplating key Stage III trials in NSCLC

With regards to today’s focus on a phase 2 randomised controlled trial (RCT), it is an intriguing development to be thinking about because usually it is phase 3 trials which tend to be rather controversial and generate a lot of reader questions.  This especially true when it’s a negative study and people want to know why, or what on earth happened?!

Between the lonely sea and sky…

It’s rare for a positive phase 2 trial to lead to more questions than any other studies being presented at a given cancer conference.

I must admit this was probably my favourite data of the ESMO meeting because it offers plenty of possibilities and also broader encouragement for the field when you consider how many studies have tried to manipulate the tumour microenvironment and not succeeded.

Between the current readout and the forthcoming pivotal phase 3 trial, however, lie a number of key questions which need to be addressed, as well as plenty of subtleties and nuance to think about carefully.

So what’s in store on the lung cancer front?

BSB subscribers can read up on our latest commentary and analysis from the ESMO conference, including expert opinions and reactions – you can log-in or click to access our latest analysis.

This content is restricted to subscribers

error: Content is protected !!